| http://www.w3.org/ns/prov#value | - About IABPs for acute coronary syndrome???a Class II indication???the FDA writes: ???Trials performed to investigate the benefit of IABP using the modern standard of care have been underpowered to demonstrate improvement, or have had other limitations, such as variability in the timing of IABP usage.??? The reference to timing is an attempt to explain the results from the IABP SHOCK II trial, whic
|
